{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091991","form_type":"8-K","ticker":"ASH","cik":"0001674862","company_name":"ASHLAND INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.059531+00:00","generated_at":"2026-05-31T12:19:39.959232+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ashland Q3 adjusted EBITDA up 5% to $139M; adjusted EPS $1.49 beats prior year $1.23","bullets":["Sales $544M flat YoY; adjusted EBITDA $139M (+5%) on volume gains, favorable mix, and deflationary raw materials.","GAAP continuing ops EPS $0.60 vs $0.79; adjusted EPS excl. intangibles amortization $1.49 vs $1.23.","Repurchased 1.3M shares during Q3; $770M remaining under authorization.","Operating cash flow $128M; ongoing free cash flow $112M, up from $97M in prior-year quarter.","Personal Care and Specialty Additives volume growth offset by weaker Life Sciences; June softer than expected."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091991","json":"https://secwatch.observer/filing/0000950170-24-091991.json","markdown":"https://secwatch.observer/filing/0000950170-24-091991.md","text":"https://secwatch.observer/filing/0000950170-24-091991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674862/000095017024091991/0000950170-24-091991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674862/000095017024091991/ash-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:19:39.959232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}